Evidence map›Paper›PMID 42640449›Full record

ArticleInternational journal of hematology2026

Persistent parkinsonism with dopaminergic denervation following axicabtagene ciloleucel therapy for diffuse large B cell lymphoma: a case report.

Wataru Kinoshita, Michiaki Sato, Yuya Kurihara, Arika Shimura, Akira Honda, Yosuke Masamoto, Ayaka Seki, Meiko Maeda, Wataru Satake, Mineo Kurokawa

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wataru KinoshitaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-City, Tokyo, 113-8655, Japan.
Michiaki SatoDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-City, Tokyo, 113-8655, Japan.
Yuya KuriharaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-City, Tokyo, 113-8655, Japan.
Arika ShimuraDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-City, Tokyo, 113-8655, Japan.
Akira HondaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-City, Tokyo, 113-8655, Japan.
Yosuke MasamotoDepartment of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Ayaka SekiDepartment of Neurology, The University of Tokyo, Tokyo, Japan.
Meiko MaedaDepartment of Neurology, The University of Tokyo, Tokyo, Japan.
Wataru SatakeDepartment of Neurology, The University of Tokyo, Tokyo, Japan.
Mineo KurokawaDepartment of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-City, Tokyo, 113-8655, Japan. kurokawa@m.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-4034-2422

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While immune effector cell-associated neurotoxicity syndrome (ICANS) remains one of the major adverse events in CD19-targeted CAR-T cell therapy, neurodegenerative-like movement disorders are characteristically associated with BCMA-targeted therapies, not CD19. We report a distinct case of persistent parkinsonism that became evident during recurrent neurological deterioration accompanied by a decline in ICE score in a patient treated with axicabtagene ciloleucel for relapsed diffuse large B cell lymphoma. Notably,

Indexed as

CD19 CAR-T cell therapyDiffuse large B cell lymphomaICANSNeurotoxicityParkinsonism

Identifiers

PMID42640449

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.